Launch of our new TRICALS website

We are pleased to announce the official launch of our brand-new TRICALS…

Words Michael van der Linde.Published April 20, 2020
Launch of our new TRICALS website

We are pleased to announce the official launch of our brand-new TRICALS website! Our new website provides up-to-date information about TRICALS and has many new features. 

What’s new?

We have reviewed all the existing information and added a range of new content to the website, such as:

  • you will easily find new information about upcoming clinical trials, such as the MAGNET platform trial.
  • We will now keep you updated about developments and achievements of TRICALS on our News page. So keep an eye on this webpage if you want to stay informed about the latest news or sign up for our newsletter.
  • In addition, on our new fundraising page you can read more about how you can help us in our mission. We now support the option to start your own fundraising campaign or you can donate to TRICALS directly. On our fundraising page you can read more about setting up your own campaign or you can take a look at existing ones.
  • We have also listed our future events for you on our Events page. Why not find out if we have anything planned near you?

So for now, take some time to explore our new website and we hope you like it as much as we do!


Share
Our upcoming trials
Active
Phase ii

RT001 in Amyotrophic Lateral Sclerosis

Industry trial
In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS. This clinical trial is sponsored by Retrotope Inc.
Read more
Active
Phase iii

ALXN1210-ALS-308 trial

Industry trial
This phase 3 trial aims to study the safety and efficacy of the drug ‘ravulizumab’ in people living with ALS. To register for this study, you should contact your local ALS centre or treating physician.
Read more
Active
Phase iii

VALOR study

Industry trial
Biogen is conducting a clinical trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS) with a SOD1 gene mutation.
Read more
Recruiting
Phase iii

TUDCA-ALS

Investigator initiated trial
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.
Read more

Related news

The Lalji Family ALS Award
The Lalji Family ALS Award
The Lalji Family ALS Award is a global prize celebrating excellence in […]
More patients eligible for treatment research through innovative study design
More patients eligible for treatment research through innovative study design
Due to a new trial design for treatment research, more ALS patients […]
Amylyx Pharmaceuticals and TRICALS to collaborate on phase 3 clinical trial
Amylyx Pharmaceuticals and TRICALS to collaborate on phase 3 clinical trial
Today, Amylyx Pharmaceuticals provided an update on its plans to advance its […]
Retrotope announces initiation of RT001 study in people with ALS
Retrotope announces initiation of RT001 study in people with ALS
Retrotope Inc has announced that the first participants have been enrolled in […]